哈工智能(000584.SZ):參投併購基金擬將所持哈工藥機17.22%股權轉讓給無錫維動
格隆匯12月9日丨哈工智能(000584.SZ)公佈,2021年12月9日,公司參與投資的嘉興大直機器人產業股權投資合夥企業(有限合夥)(“併購基金”)與無錫維動機器人有限公司(“無錫維動”)簽訂《江蘇哈工藥機科技股份有限公司之股權轉讓協議》,根據雙方友好協商,併購基金將其持有的江蘇哈工藥機科技股份有限公司(“目標公司”)17.2249%的股權全部轉讓給無錫維動,轉讓價格為4091萬元。交易完成後,併購基金不再持有目標公司的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.